AKT1 and cancer: Our study shows that HS acts simultaneously on a variety of signaling pathways related to CRC, such as the PI3K-Akt signaling pathway, proteoglycans in cancer, and the MAPK signaling pathway, which provides a reference for the research on the specific mechanism of the drug in the treatment of CRC.